---
layout: post
title: New Drug Approvals 2011 - Pt. XXVI - Icatibant (FirazyrTM)
date: '2011-08-30T14:17:00.004+01:00'
author: Patricia
tags:
- 2011 New Drugs
- Peptide Drugs
modified_time: '2011-09-07T09:05:39.180+01:00'
thumbnail: http://3.bp.blogspot.com/-ThdA-_7zYGk/TlwNb5f5oAI/AAAAAAAAAn4/9n84nEEmXms/s72-c/firazyr.gif
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-8026584334319689843
blogger_orig_url: http://chembl.blogspot.com/2011/08/new-drug-approvals-2011-pt-xxvi.html
---

<a href="http://3.bp.blogspot.com/-ThdA-_7zYGk/TlwNb5f5oAI/AAAAAAAAAn4/9n84nEEmXms/s1600/firazyr.gif"><img alt="" border="0" id="BLOGGER_PHOTO_ID_5646402805758009346" src="http://3.bp.blogspot.com/-ThdA-_7zYGk/TlwNb5f5oAI/AAAAAAAAAn4/9n84nEEmXms/s400/firazyr.gif" style="cursor: hand; cursor: pointer; display: block; height: 103px; margin: 0px auto 10px; text-align: center; width: 296px;" /></a><br />
<div style="text-align: left;"></div><br />
<br />
<center> <img src="https://www.ebi.ac.uk/chembltools/autoiconlarge/5,0,1,0,1,0,1,0,0" width="400" /> </center><center><br />
</center> <br />
<div class="separator" style="clear: both; text-align: -webkit-auto;"></div><div class="separator" style="clear: both; text-align: center;">ATCC: <a href="http://www.whocc.no/atc_ddd_index/?code=C01EB19">C01EB19</a></div><div class="separator" style="clear: both; text-align: center;">Wikipedia: <a href="http://en.wikipedia.org/wiki/Icatibant">Icatibant</a></div><div class="separator" style="clear: both; text-align: center;"><br />
</div><div class="separator" style="clear: both; text-align: center;"></div><span class="Apple-style-span" style="font-family: inherit;">On the August 25th 2011, the FDA approved Icatibant (trade name: <a href="http://www.trademarkia.com/trademarks-search.aspx?tn=firazyr">Firazyr</a><sup>TM</sup>), a <a href="http://en.wikipedia.org/wiki/Bradykinin_receptor_B2">bradykinin B2 receptor (B2R)</a> <a href="http://en.wikipedia.org/wiki/Receptor_antagonist">antagonist</a> indicated for the treatment of acute attacks of <a href="http://en.wikipedia.org/wiki/Hereditary_angioedema">hereditary angioedema (HAE)</a> in patients aged 18 or older.</span><br />
<span class="Apple-style-span" style="font-family: inherit;"><br />
</span><br />
<div><span class="Apple-style-span" style="font-family: inherit;"> </span></div><div><span class="Apple-style-span" style="font-family: inherit;">HAE is a rare genetic disease and is caused by low levels of <a href="http://en.wikipedia.org/wiki/C1-inhibitor">C1-esterase inhibitor (C1-INH)</a>, the major endogenous inhibitor and regulator of the protease <a href="http://en.wikipedia.org/wiki/Kallikrein#Plasma_kallikrein">plasma kallikrein</a> and the key regulator of the <a href="http://en.wikipedia.org/wiki/Kinin-kallikrein_system">Factor XII/kallikrein</a> cascade. One component this cascade is the production of <a href="http://en.wikipedia.org/wiki/Bradykinin">bradykinin</a> by plasma kallikrein. During HAE attacks, disregulated activity of plasma kallikrein leads to excessive bradykinin production; bradykinin is a potent vasodilator, which s thought to be responsible for the characteristic HAE symptoms of localised swelling, inflammation and pain.</span><br />
<span class="Apple-style-span" style="font-family: inherit;"><br />
</span></div><div style="text-align: center;"><span class="Apple-style-span" style="font-family: inherit;"> </span></div><div><span class="Apple-style-span" style="font-family: inherit;">Icatibant </span><span class="Apple-style-span" style="font-family: inherit;">treats the clinical symptoms of HAE attack by selective- and competitively binding, as an antagonist, to the B2 bradykinin receptor (B2R) (Uniprot: <a href="http://www.uniprot.org/uniprot/P30411">P30411</a>; ChEMBL ID: <a href="https://www.ebi.ac.uk/chembldb/target/inspect/CHEMBL3157">CHEMBL3157</a>; PFAM: <a href="http://pfam.sanger.ac.uk/family/7tm_1">PF00001</a>), with similar affinity to bradykinin (1-10 nM for the B2R, while affinity for the B1R is 100-fold lower). Icatibant is the first in class agent against this target. The -tibant stem covers bradykinin antagonists.</span><br />
<span class="Apple-style-span" style="font-family: inherit;"><br />
</span><br />
<span class="Apple-style-span" style="font-family: inherit;">B2R is a <a href="http://en.wikipedia.org/wiki/Rhodopsin-like_receptors">Rhodopsin-like receptor</a>, 391 amino acid long, which belongs to the <a href="http://en.wikipedia.org/wiki/Rhodopsin-like_receptors#Subfamily_A3">G protein-coupled receptor (GPCR) A3 family</a> and is encoded by the BDKRB2 gene in humans. The amino acid sequence of B2R is:</span><br />
<span class="Apple-style-span" style="font-family: inherit;"><br />
</span></div><div><pre>&gt;B2R 
MFSPWKISMFLSVREDSVPTTASFSADMLNVTLQGPTLNGTFAQSKCPQVEWLGWLNTIQ
PPFLWVLFVLATLENIFVLSVFCLHKSSCTVAEIYLGNLAAADLILACGLPFWAITISNN
FDWLFGETLCRVVNAIISMNLYSSICFLMLVSIDRYLALVKTMSMGRMRGVRWAKLYSLV
IWGCTLLLSSPMLVFRTMKEYSDEGHNVTACVISYPSLIWEVFTNMLLNVVGFLLPLSVI
TFCTMQIMQVLRNNEMQKFKEIQTERRATVLVLVVLLLFIICWLPFQISTFLDTLHRLGI
LSSCQDERIIDVITQIASFMAYSNSCLNPLVYVIVGKRFRKKSWEVYQGVCQKGGCRSEP
IQMENSMGTLRTSISVERQIHKLQDWAGSRQ</pre></div><div><span class="Apple-style-span" style="font-family: inherit;">There are no known experimental structures of B2R, ho</span>wever there are several relevant homologous structures of other members of the rhodopsin-like GPCR family (see <a href="http://chembl.blogspot.com/p/gpcr-structures.html">here</a> for a current list).</div><div><span class="Apple-style-span" style="font-family: inherit;"> </span></div><div><span class="Apple-style-span" style="font-family: inherit;">Icatibant is the third drug approved in the US to treat HAE attacks. Previous drugs include <a href="http://chembl.blogspot.com/2009/12/first-approval-of-last-month-of-2009-is.html">Ecallantide</a> (approved in December 2009 under the trade name Kalbitor), which </span>is a potent, selective, reversible inhibitor of plasma kallikrein, and C1-INH (approved in October 2009 under the trade name Berinert), which is a freeze-dried human C1-esterase inhibitor concentrate.<br />
<br />
</div><div><span class="Apple-style-span" style="font-family: inherit;"> </span></div><div><span class="Apple-style-span" style="font-family: inherit;"><img alt="" border="0" id="BLOGGER_PHOTO_ID_5646401034650328370" src="http://1.bp.blogspot.com/-eDzXSJl5sNE/TlwL0zm7HTI/AAAAAAAAAno/aDf-NZCKLic/s400/Icatibant.png" style="cursor: hand; cursor: pointer; display: block; height: 273px; margin: 0px auto 10px; text-align: center; width: 400px;" /></span></div><div><span class="Apple-style-span" style="font-family: inherit;"> </span></div><div><span class="Apple-style-span" style="font-family: inherit;">Icatibant </span><span class="Apple-style-span" style="font-family: inherit;">(IUPAC: (2S)-2-[[(3aS,7aS)-1-[2-[(2S)-2-[[(2S)-2-[[2-[[(4R)-1-[1-[2-[[(2R)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-3-thiophen-2-ylpropanoyl]amino]-3-hydroxypropanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid; ChEMBL ID: <a href="https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL375218">CHEMBL375218</a>; PubChem: <a href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=71364&amp;loc=ec_rcs">71364</a></span><span class="Apple-style-span" style="font-family: inherit;">; ChemSpider: <a href="http://www.chemspider.com/Chemical-Structure.5293384.html">5293384</a></span><span class="Apple-style-span" style="font-family: inherit;">) </span>is a synthetic decapeptide that differs from bradykinin (a nonapeptide with an amino acid sequence RPPGFSPFR) at the amino acids' positions 3, 5, 7 and 8, which have been replaced  by four non-natural amino acids, and also in one additional amino acid (a D-arginine) at the N-terminus of the bradykinin arginine at position 1. Thus, Icatibant amino acid sequence is D-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-D-Tic-Oic-Arg. These modifications prevent Icatibant from being metabolised by major bradykinin-metabolizing enzymes, which makes it more stable that bradykinin. Icatibant has a molecular weight of 1304.5 Da.<br />
<br />
</div><div><span class="Apple-style-span" style="font-family: inherit;"> </span></div><div><span class="Apple-style-span" style="font-family: inherit;">Icatibant can be self-administrated through an injection in the abdominal area, thus providing a new option for the treatment of acute HAE attacks. The recommended dose is 30 mg administrated subcutaneously. In the case of inadequate response or recurrence of symptoms, additional dose may be administrated at intervals of at least 6 hours, with no more than 3 doses administrated in any 24-hour period (recommended daily dose equivalent 69.0 umol).&nbsp;</span><br />
<span class="Apple-style-span" style="font-family: inherit;"><br />
</span></div><div><span class="Apple-style-span" style="font-family: inherit;"> </span></div><div><span class="Apple-style-span" style="font-family: inherit;">Following a 30 mg subcutaneous dose, the absolute bioavailability of Icatibant is ca. 97%, with a plasma clearance of 245 mL/min, a mean elimination half-life of 1.4 hours and a volume of distribution of 29 L. Icatibant is extensively metabolised by proteolytic enzymes to inactive metabolites that are primarily excreted in the urine, with &lt;10% of the dose eliminated as unchanged drug. As would be anticipated for a peptide drug, Icatibant is not an inhibitor of major cytochrome P450 (CYP) isoenzymes and is not an inducer of CYP 1A2 and 3A4.</span></div><div></div><div><span class="Apple-style-span" style="font-family: inherit;"><br />
</span><br />
<span class="Apple-style-span" style="font-family: inherit;">The full prescribing information can be found&nbsp;<a href="http://pi.shirecontent.com/PI/PDFs/Firazyr_USA_ENG.pdf">here</a>.</span><br />
<span class="Apple-style-span" style="font-family: inherit;"><br />
</span><br />
<span class="Apple-style-span" style="font-family: inherit;">Icatibant is marketed by <a href="http://www.shire.com/shireplc/en/home">Shire Human Genetic Therapies Inc</a>. and the product website is <a href="http://www.firazyr.com/">www.firazyr.com</a> (Since 2008, Icatibant has been approved for use in the European Union; the european SPC can be found <a href="http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000899/WC500022966.pdf">here</a>).</span></div>